Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe Sells 12,651 Shares

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 12,651 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $16.79, for a total value of $212,410.29. Following the completion of the transaction, the chief financial officer now owns 211,000 shares of the company’s stock, valued at $3,542,690. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, September 3rd, Oluyemi Okupe sold 11,609 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.60, for a total value of $169,491.40.
• On Tuesday, June 25th, Oluyemi Okupe sold 11,546 shares of Hims & Hers Health stock. The shares were sold at an average price of $22.21, for a total value of $256,436.66.

Hims & Hers Health Trading Up 0.7 %

Shares of Hims & Hers Health stock traded up $0.11 on Monday, reaching $16.41. 3,947,375 shares of the company were exchanged, compared to its average volume of 7,744,376. Hims & Hers Health, Inc. has a one year low of $5.65 and a one year high of $25.74. The company has a market capitalization of $3.52 billion, a price-to-earnings ratio of -1,646.00 and a beta of 1.05. The company has a 50-day moving average of $17.35 and a 200 day moving average of $17.09.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a return on equity of 5.25% and a net margin of 1.70%. The business had revenue of $315.65 million for the quarter, compared to analysts’ expectations of $302.43 million. During the same quarter in the prior year, the business earned ($0.03) EPS. The firm’s revenue for the quarter was up 51.8% on a year-over-year basis. Analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently added to or reduced their stakes in HIMS. Renaissance Technologies LLC raised its stake in Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after acquiring an additional 3,205,108 shares during the period. Farallon Capital Management LLC raised its stake in Hims & Hers Health by 3,890.5% in the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares during the period. M&G Plc bought a new stake in Hims & Hers Health in the 1st quarter valued at $8,232,000. Healthcare of Ontario Pension Plan Trust Fund raised its stake in Hims & Hers Health by 164.1% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock valued at $10,663,000 after acquiring an additional 328,142 shares during the period. Finally, State of Michigan Retirement System raised its stake in Hims & Hers Health by 177.8% in the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock valued at $10,095,000 after acquiring an additional 320,000 shares during the period. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft boosted their price objective on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research report on Wednesday, August 7th. Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. TD Cowen upped their price target on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Truist Financial upped their price target on Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research report on Thursday, July 18th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $18.00 price target on shares of Hims & Hers Health in a research report on Tuesday, August 6th. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.